Related references
Note: Only part of the references are listed.Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects
Pratap Neelakantan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
ALK inhibitors in the treatment of advanced NSCLC
Cesare Gridelli et al.
CANCER TREATMENT REVIEWS (2014)
GlyT1 inhibitor reduces oscillatory potentials of the electroretinogram in rats
Chang-Ning Liu et al.
CUTANEOUS AND OCULAR TOXICOLOGY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Crizotinib: A New Treatment Option for ALK-Positive Non-Small Cell Lung Cancer
Cindy L. O'Bryant et al.
ANNALS OF PHARMACOTHERAPY (2013)
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study
Takashi Seto et al.
LANCET ONCOLOGY (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Tyrosine kinase gene rearrangements in epithelial malignancies
Alice T. Shaw et al.
NATURE REVIEWS CANCER (2013)
Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)
Kazutomo Kinoshita et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge et al.
LANCET ONCOLOGY (2012)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
Sai-Hong Ignatius Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing
Ke-Ping Xu et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2007)
Role of tyrosine kinase inhibitors in cancer therapy
A Arora et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Recommendations for a toxicological screening ERG procedure in laboratory animals
SG Rosolen et al.
DOCUMENTA OPHTHALMOLOGICA (2005)
Oscillatory potential analysis and ERGs of normal and diabetic rats
HA Hancock et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2004)
Dark adaptation is faster in pigmented than albino rats
D Behn et al.
DOCUMENTA OPHTHALMOLOGICA (2003)
Share Paper
